179 related articles for article (PubMed ID: 22594514)
1. Pharmacogenetics of statins: achievements, whole-genome analyses and future perspectives.
Postmus I; Verschuren JJ; de Craen AJ; Slagboom PE; Westendorp RG; Jukema JW; Trompet S
Pharmacogenomics; 2012 May; 13(7):831-40. PubMed ID: 22594514
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomics of lipid-lowering therapies.
Hu M; Tomlinson B
Pharmacogenomics; 2013 Jun; 14(8):981-95. PubMed ID: 23746191
[TBL] [Abstract][Full Text] [Related]
3. In search for genetic determinants of clinically meaningful differential cardiovascular event reduction by pravastatin in the PHArmacogenetic study of Statins in the Elderly at risk (PHASE)/PROSPER study.
Postmus I; Johnson PC; Trompet S; de Craen AJ; Slagboom PE; Devlin JJ; Shiffman D; Sacks FM; Kearney PM; Stott DJ; Buckley BM; Sattar N; Ford I; Westendorp RG; Jukema JW
Atherosclerosis; 2014 Jul; 235(1):58-64. PubMed ID: 24816038
[TBL] [Abstract][Full Text] [Related]
4. The genetic determinants of atorvastatin response.
Rodrigues AC; Hirata MH; Hirata RD
Curr Opin Mol Ther; 2007 Dec; 9(6):545-53. PubMed ID: 18041665
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenomics of statin response.
Mangravite LM; Wilke RA; Zhang J; Krauss RM
Curr Opin Mol Ther; 2008 Dec; 10(6):555-61. PubMed ID: 19051133
[TBL] [Abstract][Full Text] [Related]
6. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Mora S; Ridker PM
Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
[TBL] [Abstract][Full Text] [Related]
7. Replication of LDL GWAs hits in PROSPER/PHASE as validation for future (pharmaco)genetic analyses.
Trompet S; de Craen AJ; Postmus I; Ford I; Sattar N; Caslake M; Stott DJ; Buckley BM; Sacks F; Devlin JJ; Slagboom PE; Westendorp RG; Jukema JW;
BMC Med Genet; 2011 Oct; 12():131. PubMed ID: 21977987
[TBL] [Abstract][Full Text] [Related]
8. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.
Pedersen TR
Am J Cardiovasc Drugs; 2010; 10 Suppl 1():10-7. PubMed ID: 21391729
[TBL] [Abstract][Full Text] [Related]
9. Genetic determinants of response to statins.
Peters BJ; Klungel OH; de Boer A; Maitland-van der Zee AH
Expert Rev Cardiovasc Ther; 2009 Aug; 7(8):977-83. PubMed ID: 19673675
[TBL] [Abstract][Full Text] [Related]
10. Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial.
Chasman DI; Giulianini F; MacFadyen J; Barratt BJ; Nyberg F; Ridker PM
Circ Cardiovasc Genet; 2012 Apr; 5(2):257-64. PubMed ID: 22331829
[TBL] [Abstract][Full Text] [Related]
11. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk.
Robinson JG
Am J Cardiol; 2008 Apr; 101(7):1009-15. PubMed ID: 18359323
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomics of statin response.
Mangravite LM; Krauss RM
Curr Opin Lipidol; 2007 Aug; 18(4):409-14. PubMed ID: 17620857
[TBL] [Abstract][Full Text] [Related]
13. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
Harley CR; Gandhi SK; Heien H; McDonough K; Nelson SP
Expert Opin Pharmacother; 2008 Apr; 9(5):669-76. PubMed ID: 18345946
[TBL] [Abstract][Full Text] [Related]
14. Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy.
Rosenson RS
Am Heart J; 2006 Mar; 151(3):556-63. PubMed ID: 16504615
[TBL] [Abstract][Full Text] [Related]
15. Non-response to (statin) therapy: the importance of distinguishing non-responders from non-adherers in pharmacogenetic studies.
Trompet S; Postmus I; Slagboom PE; Heijmans BT; Smit RA; Maier AB; Buckley BM; Sattar N; Stott DJ; Ford I; Westendorp RG; de Craen AJ; Jukema JW
Eur J Clin Pharmacol; 2016 Apr; 72(4):431-7. PubMed ID: 26686871
[TBL] [Abstract][Full Text] [Related]
16. Statins personalized.
Superko HR; Momary KM; Li Y
Med Clin North Am; 2012 Jan; 96(1):123-39. PubMed ID: 22391257
[TBL] [Abstract][Full Text] [Related]
17. Statins: are any questions unanswered?
Kearney PM; Baigent C
Curr Opin Lipidol; 2006 Aug; 17(4):418-25. PubMed ID: 16832166
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenomics of statin responsiveness.
Kajinami K; Akao H; Polisecki E; Schaefer EJ
Am J Cardiol; 2005 Nov; 96(9A):65K-70K; discussion 34K-35K. PubMed ID: 16291017
[TBL] [Abstract][Full Text] [Related]
19. Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials?
Ray KK; Cannon CP; Ganz P
Am J Cardiol; 2006 Dec; 98(11A):18P-25P. PubMed ID: 17126675
[TBL] [Abstract][Full Text] [Related]
20. Non-cardiovascular mortality, low-density lipoprotein cholesterol and statins: a meta-regression analysis.
Razzolini R; Tarantini G; Ossena G; Favaretto E; Bilato C; Manzato E; Dalla-Volta S; Iliceto S
Cardiology; 2008; 109(2):110-6. PubMed ID: 17700016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
